A

ALLO

ALLO

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
0%Bearish
Buy/Sell Ratio0% buys
BearishBullish
ALLO Live QuoteReal-time
$0.67
$0.66(-49.86%)1M
Day Range$0.65 – $0.72
Open$0.70
Previous Close$0.70
Volume7.41M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$231.06M
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-0.61
Price to Book0.6
Dividend Yield0.65%
Beta (Volatility)0.78
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $0.67 (0%)
Low: $0.65High: $4.46
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$9.00-94.0% upside

Insider Buys

0

$0

Insider Sales

1

$49K

Total Volume

$49K

1 transactions

Net Activity

$49K

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
35CONFIDENCE

Sentiment Rating

Moderate Distribution

CEO Conviction Index

No Recent Signal

Key Drivers

  • •Heavy distribution: sales represent 100% of total transaction value.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
P
1

Parker Geoffrey M.

CFO

0 buys1 sells

$49K total

Trading History
ALLO insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Oct 21, 2026

1 months ago

Parker Geoffrey M.

CFO

CFO
Sell36.3K$1.34$49K
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
ALLO Buy Conviction0%
Industry Rank#0 of 569
Volume Contribution0.0%
Total Industry Activity$16.52B

ALLO has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for ALLO

Over the last 90 days, corporate insiders at ALLO (ALLO) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 1 were sales. The total volume of insider trading reached $49K.

The net insider activity for ALLO shows a net selling bias of $49K. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Parker Geoffrey M. (CFO), who traded 36.3K shares valued at $49K on Oct 21, 2026.

Live Market News & Developments
Aggregated real-time headlines for ALLO (ALLO)
6 updates

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Yahoo Finance95d ago

Allogene: If MRD Holds, This Becomes A Completely Different Company

Seeking Alpha75d ago

Allogene stock sails after CAR T clears residual lymphoma in early data cut

BioSpace221d ago

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

Yahoo Finance70d ago

ALLO Stock Soars As ALPHA3 Trial Data Reset Expectations

timothysykes.com218d ago

$ALLO stock is up 11% today. Here's what we see in our data.

Quiver Quantitative114d ago

Related News & Analyst Reports

Read original insights and educational research covering ALLO and the Unknown sector.

August 4, 2026

The Spinoff Separation: Tracking Post-Spinoff Executive Ownership Trends

An investigation of corporate spinoffs, showing how executive equity allocations and post-separation insider transactions signal parent and subsidiary performance trajectories.

Read Analysis
March 14, 2025

Rule 10b5-1 Trading Plans: What Investors Need to Know

Rule 10b5-1 plans allow insiders to pre-schedule trades while aware of material information, but the 2023 SEC reforms added mandatory cooling-off periods. This guide explains the new rules and what changed for investors tracking insider activity.

Read Analysis
January 20, 2025

Insider Buying vs. Stock Buybacks: Which Signal Should You Follow?

Corporate buybacks and insider purchases are both bullish signals — but they differ fundamentally in what they mean, how reliable they are, and how you should incorporate them into your investment analysis. This guide breaks down the mechanics, academic research, and practical applications of both signals.

Read Analysis
January 18, 2025

Rule 10b5-1 Trading Plans: What Every Investor Must Know

Rule 10b5-1 plans allow corporate insiders to pre-schedule stock sales months in advance, providing them with an affirmative defense against insider trading allegations. This guide explains how these plans work, why they matter for interpreting insider transaction data, and the significant regulatory changes made by the SEC in 2023.

Read Analysis
June 7, 2023

Institutional Ownership vs. Insider Holdings: Who Has More Influence?

When BlackRock and Vanguard own 15% of a company and the CEO owns 0.5%, whose incentives drive capital allocation decisions? This report compares activist institutional pressure against insider ownership depth as governance indicators.

Read Analysis

FAQs About ALLO Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for ALLO.

Based on SEC Form 4 disclosures, the Insider Confidence Score for ALLO is currently 35/100, which reflects a moderate distribution bias. This calculation accounts for a total of 0 purchases and 1 sales by company executives over the last 90 days.

The CEO Conviction Index for ALLO is rated as "No Recent Signal". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.